Compare IDEXX Laboratories, Inc. (IDXX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs VNET Group Inc — how do they compare? IDEXX Laboratories, Inc. trades at $519.37 (market cap $40.43B), while VNET Group Inc trades at $5.36 (market cap $1.47B). The key difference: IDEXX Laboratories, Inc. is far larger — about 27.5× VNET Group Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 4,955,295). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and VNET Group Inc for 16 Days on average.
| IDXX | VNET | |
|---|---|---|
Market Cap | $40.43B | $1.47B |
Volume | 692,164 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $766.68 | $14.03 |
52-Week Low | $504.70 | $5.13 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $41.32B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
VNET trades at $5.46, up 1.3% today but near 52-week lows, with a bearish technical signal. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Recent news includes a strategic investment closing and a cooperation agreement with CATL, providing some positive catalysts amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst sentiment is moderately bullish with 62.5% buy ratings. Key risks include balance sheet strain from negative cash flow and competitive pressures in the data center market. Upside potential hinges on execution of new partnerships and demand for AI infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
